**Name of Journal:** *World Journal of Psychiatry*

**Manuscript NO:** 84048

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Effect of hyperbaric oxygen on post-stroke depression**

Guo H *et al*. Hyperbaric oxygen on post-stroke depression

Hong Guo, Yi-Ran Ge, Yan-Bin Dong, Xiao-Chuan Zhao, Guan-Li Su, Jin-Cheng Wang

**Hong Guo, Yan-Bin Dong,** Department of Psychology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China

**Yi-Ran Ge,** Department of Clinical Psychology, The First Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China

**Xiao-Chuan Zhao, Guan-Li Su, Jin-Cheng Wang,** Department of Psychiatry, The First Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China

**Author contributions:** Guo H and Ge YR concepted the study; Guo H, Dong YB and Zhao XC collected the data; Guo H, Zhao XC, Wang JC and Ge YR contributed to the formal analysis; Guo H and Zhao XC contributed to the investigation; Guo H, Zhao XC and Su GL contributed to the methodology; Guo H, Zhao XC, Su GL and Dong YB supervised the study; Zhao XC validated the study; Guo H and Ge YR contributed to the visualization of the study; Guo H and Wang JC originally drafted the manuscript; Guo H, Ge YR, Wang JC and Dong YB reviewed and edited the manuscript.

**Corresponding author: Jin-Cheng Wang, PhD, Chief Doctor,** Department of Psychiatry, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Shijiazhuang 050000, Hebei Province, China. 757451886@qq.com

**Received:** March 8, 2023

**Revised:** April 8, 2023

**Accepted:** April 12, 2023

**Published online:**

**Abstract**

BACKGROUND

In patients with post-stroke depression (PSD) in diabetes, the situation may be more complex, requiring simultaneous treatment of blood glucose, depressive symptoms, and neurological dysfunction. Hyperbaric oxygen (HBO) therapy can improve tissue oxygen content and improve the situation of ischemia and hypoxia, thus playing a role in protecting brain cells and restoring the function of brain cells. However, there are few studies on HBO therapy for patients with PSD. This study explores the clinical efficacy of such therapy for stroke complicated with depression and diabetes mellitus, and to provide reference and basis for clinical treatment and development through the application of relevant rating scales and laboratory test indicators.

AIM

To evaluate the clinical effects of HBO therapy on patients with diabetes with PSD.

METHODS

A total of 190 diabetic patients with PSD were randomly divided into observation and control groups (95 patients per group). The control group received escitalopram oxalate 10mg once a day for eight weeks. In addition, the observation group was also given HBO therapy, once a day, five times a week, for eight weeks. The Montgomery Depression Rating Scale (MADRS), National Institutes of Health Stroke Scale (NIHSS), hypersensitive C-reactive protein, tumor necrosis factor (TNF)-α, and fasting glucose levels were compared.

RESULTS

There were no significant differences in age, sex, or depression course between the groups (*P* > 0.05). After HBO treatment, MADRS scores in both groups decreased significantly (14.3 ± 5.2), and were significantly lower in the control group (18.1 ± 3.5). After HBO treatment, NIHSS scores in both groups decreased significantly, and scores in the observation group (12.2 ± 4.0) decreased more than in the control group (16.1 ± 3.4), the difference was statistically significant (*P* < 0.001). The levels of hypersensitive C-reactive protein and TNF-α in both groups were significantly decreased, and the observation group was significantly lower than the control group (*P* < 0.001). Fasting blood glucose levels in both groups decreased significantly, and those in the observation group decreased more (8.02 ± 1.10) than in the control group (9.26 ± 1.04), with statistical significance (*t* = -7.994, *P* < 0.001).

CONCLUSION

HBO therapy can significantly improve depressive symptoms and neurological dysfunction in patients with PSD, and reduce the levels of hypersensitive C-reactive protein, TNF-α and fasting blood glucose.

**Key Words:** Hyperbaric oxygen therapy; Post-stroke depression; Diabetes; Hypersensitive C-reactive protein; Tumor necrosis factor-α; Fasting plasma glucose

Guo H, Ge YR, Dong YB, Zhao XC, Su GL, Wang JC. Effect of hyperbaric oxygen on post-stroke depression. *World J Psychiatry* 2023; In press

**Core Tip:** Post stroke depression is one of the common complications of stroke patients. It affects stroke patients in the acute phase and also occurs in the rehabilitation phase, with an incidence rate of about 33%. However, many patients with post-stroke depression may still not be diagnosed and treated. It is currently believed that biological and psychological factors are involved in the occurrence and development of post-stroke depression. Risk factors of post-stroke depression include gender, psychiatric history, size and location of stroke, poor social support and degree of physical injury. Post-stroke depression may not only affect the emotional state and quality of life of patients, but also hinder the recovery of neurological function, and even increase the mortality of patients. Studies have shown that changes in ischemic hypoxia and brain cell damage are common mechanisms of stroke and post-stroke depression, so improving ischemic hypoxia may be an effective treatment. Diabetes is a chronic disease characterized by elevated blood sugar and other metabolic disorders. diabetes is associated with an increased risk of stroke and post-stroke depression.

**INTRODUCTION**

Post-stroke depression (PSD) is a common complication in stroke patients, which can affect those in the acute stage and also occur in the convalescence stage, with an incidence of approximately 33%. However, many patients with PSD may remain undiagnosed and untreated[1]. Biological and psychological factors are currently believed to be involved in the occurrence and development of PSD[2]. Risk factors include gender, history of mental illness, size and location of stroke, poor social support, degree of physical impairment, and so on[3]. PSD may not only affect patients’ emotional state and quality of life, but also hinder the recovery of neurological function and even increase patient mortality[4]. Studies have suggested that changes in ischemic hypoxia and brain cell damage are the common mechanisms of stroke and PSD, so improving ischemic hypoxia may be an effective treatment[5]. Diabetes is a chronic disease characterized by elevated blood glucose and other metabolic disorders, and is associated with increased risk of stroke and PSD[6]. Therefore, in patients with PSD in diabetes, the situation may be more complex, requiring simultaneous treatment of blood glucose, depressive symptoms, and neurological dysfunction. Hyperbaric oxygen (HBO) therapy can improve tissue oxygen content and improve the situation of ischemia and hypoxia, thus playing a role in protecting brain cells and restoring the function of brain cells[7]. However, there are few studies on HBO therapy for patients with PSD. This study explores the clinical efficacy of such therapy for stroke complicated with depression and diabetes mellitus, and to provide reference and basis for clinical treatment and development through the application of relevant rating scales and laboratory test indicators.

**MATERIALS AND METHODS**

***Patients***

From June 2018 to June 2021, a total of 190 diabetic patients with PSD diagnosed and treated in the General Hospital of Chinese PLA were recruited, all of whom met the diagnostic criteria of PSD. Inclusion criteria: (1) Patients aged ≥ 18 years in line with PSD[8]; (2) The vital signs were stable, and the clinical laboratory indicators related to stroke were basically normal; (3) No serious complications or comorbidities, normal consciousness, and cognition; and (4) Diabetes was diagnosed before stroke and in line with the diagnostic criteria of the American Diabetes Association in 2018[9]. Exclusion criteria: (1) Complicated with serious dysfunction of heart, liver, kidney, and other organs; (2) Complicated with malignant tumor and coagulation diseases; and (3) Failure to cooperate with treatment or adherence. The study protocol was approved by the Ethics Committee of the General Hospital of Chinese PLA, and all patients or their families were informed and signed the consent. Among the 190 patients, there were 52 males and 43 females in the control group, with an average age of 63.7 ± 9.3 years, 49.2 ± 14.5 d of depression and 5.9 ± 3.4 years of diabetes. There were 55 males and 40 females in the observation group, with an average age of 62.9 ± 6.1 years, 50.1 ± 12.6 d of depression and 5.6 ± 3.6 years of diabetes. Data on the patients’ age, sex, smoking history, past disease history, and disease course were collected. The patients’ height and weight were measured, and their body mass index (BMI) was calculated. Their blood pressure was measured in the resting state.

***Patient grouping and treatment methods***

The patients were divided into observation and control groups using the random number table method, with 95 patients in each group. Patients in both groups were given nutritional cerebrovascular application (including mecobalamin 0.5 mg), once a day, three times a week, intramuscular or intravenous injection, which can be increased or decreased according to age and symptoms, anti-platelet (thromboxane A2 inhibitor aspirin, 75-100 mg/time, Once a day), hypoglycemic (exenatide’s initial dose is 5 μg twice a day, and can be increased to 10 μg twice a day after 1 mo of treatment according to the patient’s clinical response; injections should be given within 60 min before breakfast and dinner (or before 2 main meals per day; Approximately 6 h or longer)) and other conventional treatments. The control group received oral escitalopram oxalate, 10 mg, once a day (Sichuan Kelun Pharmaceutical Co., Ltd.) for eight weeks., In addition to the oral drug regimen of the control group, the observation group received HBO therapy, once a day, five times a week, for eight weeks.

The HBO treatment was as follows: an HBO chamber (OxyHealth Europe, Vitaeris 320™) was pressurized for 20 min to reach 0.25 mpa. The patient then put on a mask and breathed pure oxygen for 40 min, breathing cabin air at 10-min intervals. Finally, patients decompressed for 30 min to normal pressure, and then left the cabin. Treatment was once a day, 10 times for a course of treatment, each course of intermittent 7-10 d, for a total of two months of observation.

***Observation indicators***

The following observation indexes were used to evaluate the efficacy before and after treatment: (1) Depression evaluation: The Montgomery Depression Rating Scale (MADRS) scale was used to evaluate patients’ depression. The scale is divided into 10 items, with each item being rated from 1 to 6. On a scale of 0 to 60, the higher the score, the more severe the depression; (2) Neurological function evaluation: The National Institutes of Health Stroke Scale (NIHSS) scale was used to evaluate patients’ neurological function. The scale includes 14 items, scored from 0 to 42. The higher the score, the more severe the neurological impairment; and (3) Measurement of hypersensitive C-reactive protein and tumor necrosis factor (TNF)-α: 10 mL of fasting venous blood was taken before and after treatment, and the upper serum was centrifuged after standing. Levels of the aforementioned were determined by enzyme-linked immunosorbent assay as per the manufacturer’s instructions.

***Statistical analysis***

Enumeration data were expressed as frequencies (percentage) and the *χ*2 test was used to assess differences between the two groups. mean ± SD was used to represent measurement data, and the difference between the two groups was assessed *via* *t*-test. The differences of MADRS score, NIHSS score, hypersensitive C-reactive protein, TNF-α and fasting blood glucose levels between the two groups before and after treatment were determined by *t*-test. *P* < 0.05 was considered statistically significant (bilateral), and IBM SPSS 21.0 was used for statistical analysis of the data.

**RESULTS**

***General patient information***

This study included 190 patients with diabetes and PSD. Patients in the observation group were aged 64.4 ± 9.4 years, and male patients accounted for 57.9% (55/95). The course of depression was 50.8 ± 15.3 d, and the course of diabetes was 6.2 ± 3.6 years. The proportion of patients with hypertension, coronary heart disease and hyperlipidemia was 54.7% (52/95), 38.9% (37/95) and 66.3% (63/95), respectively. BMI of patients in the observation group was 25.8 ± 3.8 kg/m2, and systolic blood pressure was 139.2 ± 13.3 mmHg. In the observation group, 57 patients (60%) had ischemic stroke and 38 (40%) had hemorrhagic stroke. In the control group, the patients were aged 63.0 ± 9.2 years, 51.6% (49/95) male, the course of depression was 47.5 ± 13.4 d, and the course of diabetes was 5.7 ± 3.2 years. In the control group, 48.4% (46/95) had a history of hypertension, 33.7% (32/95) had a history of coronary heart disease, 54.7% (52/95) had a history of hyperlipidemia. The BMI of the control group was 26.2 ± 4.1 kg/m2, and the systolic blood pressure was 137.6 ± 12.3 mmHg. In the observation group, 48 patients (50.5%) had an ischemic stroke and 47 (49.5%) had a hemorrhagic stroke. There were no significant differences in these characteristics between the two groups (*P* > 0.05, Table 1).

***Depressive state and neurological function scores***

Before treatment, the MADRS score of observation group (33.7 ± 5.0) was not statistically significant compared with the control group (33.0 ± 4.0, *P* > 0.05). After HBO treatment, the MADRS scores in both groups decreased significantly; that of the observation group (14.3 ± 5.2) was significantly lower than that of the control group (18.1 ± 3.5), and the difference was statistically significant (*P* < 0.001). Before treatment, the NIHSS score of the observation group (21.9 ± 4.1) was compared with the control group (21.0 ± 3.9), and there was no statistical significance (*P* > 0.05). After HBO treatment, NIHSS scores in both groups decreased significantly; scores in the observation group (12.2 ± 4.0) decreased more than those in the control group (16.1 ± 3.4), the difference being statistically significant (*P* < 0.001) (Table 2).

***Levels of hypersensitive C-reactive protein and TNF-α***

Before treatment, there was no statistical significance in the level of hypersensitive C-reactive protein in the observation group (7.71 ± 1.73) compared with the control group (7.43 ± 1.53, *P* > 0.05). After HBO treatment, the level in both groups decreased significantly, and the level in the observation group (2.87 ± 1.49) was significantly lower than that in the control group (4.52 ± 1.42); the difference was statistically significant (*P* < 0.001). Before treatment, there was no significant difference in TNF-α between the observation group (57.2 ± 13.6) and control group (58.6 ± 11.9, *P* > 0.05). After HBO treatment, TNF-α in both groups decreased significantly, and decreased more in the observation group (26.7 ± 12.5) than in the control group (33.9 ± 11.1), with statistical significance (*P* < 0.001) (Table 3).

***Fasting blood glucose level***

Before treatment, there was no significant difference in fasting blood glucose level between the observation group (10.96 ± 0.91) and control group (11.16 ± 0.93). After HBO treatment, the level decreased significantly in both groups, and that in the observation group decreased more than that in the control group (9.26 ± 1.04); the difference was statistically significant (*t* = -7.994, *P* < 0.001, Table 4).

**DISCUSSION**

We found that HBO therapy improved depressive symptoms and neurological dysfunction in patients with PSD, and reduced levels of hypersensitive C-reactive protein and TNF -α compared with the control group. It is worth noting that patients with diabetes and PSD who underwent HBO therapy had lower fasting glucose levels.

Stroke is an acute cerebrovascular disease with high disability and mortality rates, and PSD is a common complication that may affect nearly one-third of patients[10-12]. Importantly, PSD not only affects the patient’s psychosis but may also affect the treatment effect and recovery of neurological dysfunction in patients with stroke, and even increase the incidence of recurrent stroke and all-cause mortality[13,14]. Diabetes, a chronic disease mainly characterized by elevated blood glucose, may increase the risk of stroke and PSD[15.16]. Additionally, PSD combined with diabetes may increase the risk of recurrent stroke, aggravate depressive symptoms, and even increase patient mortality[17]. Therefore, diabetes is a major cause of stroke. With the development of diabetes, patients are prone to metabolic abnormalities, cholesterol will be further increased, and thrombosis will be formed, finally leading to ischemic stroke[18]. Timely control of blood glucose is an important prevention of stroke.

Currently, escitalopram is the main first-line drug for the treatment of PSD, and the use of this drug can improve patients’ emotional symptoms, but studies have demonstrated that some patients with PSD still have depressive symptoms after using escitalopram, with poor efficacy[19]. Treatment includes changing the antidepressant, adding another antidepressant, or augmenting the treatment by adding another drug, such as an atypical antipsychotic or lithium. Non-pharmacological forms of augmentation of depression treatment have also been proven to be effective, including cognitive-behavioral psychotherapy, psychoeducation, aerobic exercise, neuromodulatory treatment through vagus nerve stimulation, electroconvulsive therapy (ECT), transcranial direct current stimulation (TDCS), repetitive transcranial magnetic stimulation (rTMS) or deep brain stimulation and light therapy; however, non-pharmacological forms of biological treatment used in the treatment of treatment-resistant depression also do not show substantial efficacy. Despite the improvement achieved during electroshocks, ECT has no lasting effect, and despite continued pharmacotherapy, relapses are observed in a large (37%) proportion of patients[20]. TDCS has been used with a moderate effect on depression, similar to rTMS, which also has moderate and short-term efficacy in improving mood and cognitive function in people with depression[21]. Light therapy has proven to be ineffective in enhancing the effects of antidepressants in both seasonal and recurrent depression[22]. Currently, HBO therapy is known to be an effective and safe method for treating PSD, which has been the subject of numerous studies. This study found that HBO therapy can improve depressive symptoms and neurological dysfunction in patients with PSD, specifically improving the blood supply to the lesion and facilitate the blood supply to the focal point of the stroke. Under the action of HBO, the phenomenon of counter-stealing blood will appear in the tissue, which is conducive to the blood supply to the ischemic lesion. Increase vertebrobasilar artery blood flow: Under HBO, the vertebrobasilar artery system is the only blood vessel that does not contract but dilates, thus increasing the blood supply and oxygen supply to the brain stem and reticular structure, which is conducive to the improvement of the patient’s wakefulness and mood. HBO therapy was found to improve depressive symptoms and neurological dysfunction in patients with PSD. Similar to this study, a meta-analysis established that HBO treatment reduced NIHSS scores (mean difference = 2.77 points, 95%CI from 3.57 to 1.98 points, *P* < 0.001) and improved Hamilton Depression Scale scores (mean difference = 4.33 points, 95%CI from 4.82 to 3.84 points, *P* < 0.001)[7].

Ischemic anoxic injury may be a common initiating factor of stroke and PSD, and inflammatory processes may also be involved in the occurrence and development of depression. It has been suggested that patients with PSD had higher levels of TNF-α compared with non-depressed patients (25.65 ± 9.24 *vs* 17.29 ± 4.27, *P* < 0.001)[23]. In this study, diabetic PSD patients in the observation group had lower levels of hypersensitive C-reactive protein and TNF-α compared with the control group. This suggests that inflammatory factors can be used as biomarkers of PSD in patients with diabetes and may be effective early treatment targets[24]. Interestingly, the present study found that patients with PSD and diabetes who underwent HBO therapy had lower fasting glucose levels. Previous studies have suggested that HBO therapy can promote insulin secretion in patients with diabetes and enhance glucose uptake by brain cells[25].

This study has some limitations. Owing to the small sample size, fewer variables were collected, and the observation time was short. Large randomized controlled clinical trials are required to validate the role of HBO therapy in patients with diabetes and PSD.

**CONCLUSION**

In conclusion, HBO therapy can significantly improve depressive symptoms and neurological dysfunction in patients with PSD, and reduce the levels of hypersensitive C-reactive protein, TNF-α and fasting blood glucose, which is worthy of clinical promotion.

**ARTICLE HIGHLIGHTS**

***Research background***

This study explores the clinical efficacy of such therapy for stroke complicated with depression and diabetes mellitus, and to provide reference and basis for clinical treatment and development through the application of relevant rating scales and laboratory test indicators.

***Research motivation***

Changes in ischemic hypoxia and brain cell damage are common mechanisms of stroke and post-stroke depression, so improving ischemic hypoxia may be an effective treatment. Diabetes is a chronic disease characterized by elevated blood sugar and other metabolic disorders. diabetes is associated with an increased risk of stroke and post-stroke depression.

***Research objectives***

This study explores the clinical efficacy of such therapy for stroke complicated with depression and diabetes mellitus, and to provide reference and basis for clinical treatment and development through the application of relevant rating scales and laboratory test indicators.

***Research methods***

Patients in both groups were given nutritional cerebrovascular application, once a day, three times a week, intramuscular or intravenous injection, which can be increased or decreased according to age and symptoms, anti-platelet, hypoglycemic and other conventional treatments. The control group received oral escitalopram oxalate, 10 mg, once a day for eight weeks., In addition to the oral drug regimen of the control group, the observation group received hyperbaric oxygen (HBO) therapy, once a day, five times a week, for eight weeks. The HBO treatment was as follows: an HBO chamber was pressurized for 20 min to reach 0.25 mpa. The patient then put on a mask and breathed pure oxygen for 40 min, breathing cabin air at 10-min intervals. Finally, patients decompressed for 30 min to normal pressure, and then left the cabin. Treatment was once a day, 10 times for a course of treatment, each course of intermittent 7-10 d, for a total of two months of observation.

***Research results***

There were no significant differences in age, sex, or depression course between the groups. After HBO treatment, Montgomery Depression Rating Scale scores in both groups decreased significantly, and were significantly lower in the control group. After HBO treatment, National Institutes of Health Stroke Scale scores in both groups decreased significantly, and scores in the observation group decreased more than in the control group, the difference was statistically significant. The levels of hypersensitive C-reactive protein and tumor necrosis factor (TNF)-α in both groups were significantly decreased, and the observation group was significantly lower than the control group. Fasting blood glucose levels in both groups decreased significantly, and those in the observation group decreased more than in the control group, with statistical significance.

***Research conclusions***

HBO therapy can significantly improve depressive symptoms and neurological dysfunction in patients with post-stroke depression, and reduce the levels of hypersensitive C-reactive protein, TNF-α and fasting blood glucose.

***Research perspectives***

The future research direction is mainly to study the influence of depression in diabetes patients.

**REFERENCES**

1 **Das J**, G K R. Post stroke depression: The sequelae of cerebral stroke. *Neurosci Biobehav Rev* 2018; **90**: 104-114 [PMID: 29656030 DOI: 10.1016/j.neubiorev.2018.04.005]

2 **Villa RF**, Ferrari F, Moretti A. Post-stroke depression: Mechanisms and pharmacological treatment. *Pharmacol Ther* 2018; **184**: 131-144 [PMID: 29128343 DOI: 10.1016/j.pharmthera.2017.11.005]

3 **Medeiros GC**, Roy D, Kontos N, Beach SR. Post-stroke depression: A 2020 updated review. *Gen Hosp Psychiatry* 2020; **66**: 70-80 [PMID: 32717644 DOI: 10.1016/j.genhosppsych.2020.06.011]

4 **Zhang E**, Liao P. Brain-derived neurotrophic factor and post-stroke depression. *J Neurosci Res* 2020; **98**: 537-548 [PMID: 31385340 DOI: 10.1002/jnr.24510]

5 **Loubinoux I**, Kronenberg G, Endres M, Schumann-Bard P, Freret T, Filipkowski RK, Kaczmarek L, Popa-Wagner A. Post-stroke depression: mechanisms, translation and therapy. *J Cell Mol Med* 2012; **16**: 1961-1969 [PMID: 22348642 DOI: 10.1111/j.1582-4934.2012.01555.x]

6 **Zhang Y**, He JR, Liang HB, Lu WJ, Yang GY, Liu JR, Zeng LL. Diabetes mellitus is associated with late-onset post-stroke depression. *J Affect Disord* 2017; **221**: 222-226 [PMID: 28654846 DOI: 10.1016/j.jad.2017.06.045]

7 **Liang XX**, Hao YG, Duan XM, Han XL, Cai XX. Hyperbaric oxygen therapy for post-stroke depression: A systematic review and meta-analysis. *Clin Neurol Neurosurg* 2020; **195**: 105910 [PMID: 32474256 DOI: 10.1016/j.clineuro.2020.105910]

8 **Dwyer Hollender K**. Screening, diagnosis, and treatment of post-stroke depression. *J Neurosci Nurs* 2014; **46**: 135-141 [PMID: 24670433 DOI: 10.1097/JNN.0000000000000047]

9 **American Diabetes Association**. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. *Diabetes Care* 2018; **41**: S13-S27 [PMID: 29222373 DOI: 10.2337/dc18-S002]

10 **Creutzfeldt CJ**, Holloway RG, Walker M. Symptomatic and palliative care for stroke survivors. *J Gen Intern Med* 2012; **27**: 853-860 [PMID: 22258916 DOI: 10.1007/s11606-011-1966-4]

11 **Cai H**, Wang XP, Yang GY. Sleep Disorders in Stroke: An Update on Management. *Aging Dis* 2021; **12**: 570-585 [PMID: 33815883 DOI: 10.14336/AD.2020.0707]

12 **Xiao S**, Shi L, Zhang J, Li X, Lin H, Xue Y, Xue B, Chen Y, Zhou G, Zhang C. The role of anxiety and depressive symptoms in mediating the relationship between subjective sleep quality and cognitive function among older adults in China. *J Affect Disord* 2023; **325**: 640-646 [PMID: 36657496 DOI: 10.1016/j.jad.2023.01.048]

13 **Cai W**, Mueller C, Li YJ, Shen WD, Stewart R. Post stroke depression and risk of stroke recurrence and mortality: A systematic review and meta-analysis. *Ageing Res Rev* 2019; **50**: 102-109 [PMID: 30711712 DOI: 10.1016/j.arr.2019.01.013]

14 **Niu S**, Liu X, Wu Q, Ma J, Wu S, Zeng L, Shi Y. Sleep Quality and Cognitive Function after Stroke: The Mediating Roles of Depression and Anxiety Symptoms. *Int J Environ Res Public Health* 2023; **20** [PMID: 36767777 DOI: 10.3390/ijerph20032410]

15 **Zhang Z**, Wang M, Gill D, Zhu W, Liu X. Genetically Predicted Sleep Traits and Functional Outcome After Ischemic Stroke: A Mendelian Randomization Study. *Neurology* 2023; **100**: e1159-e1165 [PMID: 36539296 DOI: 10.1212/WNL.0000000000206745]

16 **Liang ZH**, Jia YB, Li ZR, Li M, Wang ML, Yun YL, Yu LJ, Shi L, Zhu RX. Urinary biomarkers for diagnosing poststroke depression in patients with type 2 diabetes mellitus. *Diabetes Metab Syndr Obes* 2019; **12**: 1379-1386 [PMID: 31496775 DOI: 10.2147/DMSO.S215187]

17 **Hu Y**, Xing H, Dong X, Lu W, Xiao X, Gao L, Cui M, Chen J. Pioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitus. *Exp Ther Med* 2015; **10**: 1109-1114 [PMID: 26622448 DOI: 10.3892/etm.2015.2593]

18 **Maida CD**, Daidone M, Pacinella G, Norrito RL, Pinto A, Tuttolomondo A. Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases. *Int J Mol Sci* 2022; **23** [PMID: 35216512 DOI: 10.3390/ijms23042397]

19 **Starkstein SE**, Hayhow BD. Treatment of Post-Stroke Depression. *Curr Treat Options Neurol* 2019; **21**: 31 [PMID: 31236751 DOI: 10.1007/s11940-019-0570-5]

20 **Müller HHO**, Moeller S, Lücke C, Lam AP, Braun N, Philipsen A. Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use. *Front Neurosci* 2018; **12**: 239 [PMID: 29692707 DOI: 10.3389/fnins.2018.00239]

21 **Wang H**, Wang K, Xue Q, Peng M, Yin L, Gu X, Leng H, Lu J, Liu H, Wang D, Xiao J, Sun Z, Li N, Dong K, Zhang Q, Zhan S, Fan C, Min B, Zhou A, Xie Y, Song H, Ye J, Liu A, Gao R, Huang L, Jiao L, Song Y, Dong H, Tian Z, Si T, Zhang X, Li X, Kamiya A, Cosci F, Gao K, Wang Y. Transcranial alternating current stimulation for treating depression: a randomized controlled trial. *Brain* 2022; **145**: 83-91 [PMID: 35353887 DOI: 10.1093/brain/awab252]

22 **Pjrek E**, Friedrich ME, Cambioli L, Dold M, Jäger F, Komorowski A, Lanzenberger R, Kasper S, Winkler D. The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials. *Psychother Psychosom* 2020; **89**: 17-24 [PMID: 31574513 DOI: 10.1159/000502891]

23 **Mu Y**, Wang Z, Zhou J, Tan C, Wang H. Correlations of Post-stroke Depression with Inflammatory Response Factors. *Iran J Public Health* 2018; **47**: 988-993 [PMID: 30181997]

24 **Sarkar A**, Sarmah D, Datta A, Kaur H, Jagtap P, Raut S, Shah B, Singh U, Baidya F, Bohra M, Kalia K, Borah A, Wang X, Dave KR, Yavagal DR, Bhattacharya P. Post-stroke depression: Chaos to exposition. *Brain Res Bull* 2021; **168**: 74-88 [PMID: 33359639 DOI: 10.1016/j.brainresbull.2020.12.012]

25 **Al-Waili NS**, Butler GJ, Beale J, Abdullah MS, Finkelstein M, Merrow M, Rivera R, Petrillo R, Carrey Z, Lee B, Allen M. Influences of hyperbaric oxygen on blood pressure, heart rate and blood glucose levels in patients with diabetes mellitus and hypertension. *Arch Med Res* 2006; **37**: 991-997 [PMID: 17045116 DOI: 10.1016/j.arcmed.2006.05.009]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by The First Medical Center, Chinese PLA General Hospital Institutional Review Board (Approval No. 20180068).

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** We declare that there are no conflicts of interest.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 8, 2023

**First decision:** March 28, 2023

**Article in press:**

**Specialty type:** Psychology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Opuni FF, Ghana; Prati G, Italy **S-Editor:** Wang JL **L-Editor:** A **P-Editor:**

**Table 1 Clinical characteristics of patients in two groups, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Clinical characteristics** | **Observation group** | **Control group** | ***t*/*χ*2** | ***P* value** |
| Patients | 95 | 95 | - | - |
| Age (yr) | 64.4 ± 9.4 | 63.0 ± 9.2 | 1.052 | 0.294 |
| Male | 55 (57.9) | 49 (51.6) | 0.765 | 0.382 |
| Depressive course (d) | 50.8 ± 15.3 | 47.5 ± 13.4 | 1.579 | 0.116 |
| Smoking history | 38 (40.0) | 31 (32.6) | 1.115 | 0.291 |
| Diabetes course (yr) | 6.2 ± 3.6 | 5.7 ± 3.2 | 0.941 | 0.348 |
| History of hypertension | 52 (54.7) | 46 (48.4) | 0.759 | 0.384 |
| History of coronary heart disease | 37 (38.9) | 32 (33.7) | 0.569 | 0.451 |
| History of hyperlipidemia | 63 (66.3) | 52 (54.7) | 2.666 | 0.103 |
| Body mass index (kg/m2) | 25.8 ± 3.8 | 26.2 ± 4.1 | -0.676 | 0.500 |
| Systolic blood pressure (mmHg) | 139.2 ± 13.3 | 137.6 ± 12.3 | 0.873 | 0.384 |
| Stroke type |  |  | 1.724 | 0.189 |
| Ischemic stroke | 57 (60.0) | 48 (50.5) |  |  |
| Hemorrhagic stroke | 38 (40.0) | 47 (49.5) |  |  |

**Table 2 Depressive state and neurological function scores of the two groups**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | **Patients** | **MADRS scores** | **NIHSS scores** |
| **Before treatment** | **After treatment** | **Before treatment** | **After treatment** |
| Observation group | 95 | 33.7 ± 5.0 | 14.3 ± 5.2a,d | 21.9 ± 4.1 | 12.2 ± 4.0a,d |
| Control group | 95 | 33.0 ± 4.0 | 18.1 ± 3.5a | 21.0 ± 3.9 | 16.1 ± 3.4a |

a*P* < 0.001 *vs* before treatment in this group.

d*P* < 0.001 *vs* control group after treatment.

MADRS: Montgomery Depression Rating Scale; NIHSS: National Institutes of Health Stroke Scale.

**Table 3 The levels of hypersensitive C-reactive protein and tumor necrosis factor-α in the two groups**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | **Patients** | **Hypersensitive C-reactive protein (mg/L)** | **Tumor necrosis factor-α (ng/L)** |
| **Before treatment** | **After treatment** | **Before treatment** | **After treatment** |
| Observation group | 95 | 7.71 ± 1.73 | 2.87 ± 1.49a,d | 57.2 ± 13.6 | 26.7 ± 12.5a,d |
| Control group | 95 | 7.43 ± 1.53 | 4.52 ± 1.42a | 58.6 ± 11.9 | 33.9 ± 11.1a |

a*P* < 0.001 *vs* before treatment in this group.

d*P* < 0.001 *vs* control group after treatment.

**Table 4 Fasting blood glucose levels of the two groups**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Patients** | **Before treatment** | **After treatment** | ***t* value** | ***P* value** |
| Observation group | 95 | 10.96 ± 0.91 | 8.02 ± 1.10 | 20.177 | < 0.001 |
| Control group | 95 | 11.16 ± 0.93 | 9.26 ± 1.04 | 13.256 | < 0.001 |
| *t* value | - | -1.475 | -7.994 | - | - |
| *P* value | - | 0.142 | < 0.001 | - | - |